LNTH vs. TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, and QGEN
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Lantheus vs.
Lantheus (NASDAQ:LNTH) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.
Lantheus has a net margin of 28.57% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Lantheus' return on equity of 44.29% beat Teva Pharmaceutical Industries' return on equity.
Lantheus has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Lantheus presently has a consensus price target of $131.86, indicating a potential upside of 67.58%. Teva Pharmaceutical Industries has a consensus price target of $23.57, indicating a potential upside of 41.35%. Given Lantheus' stronger consensus rating and higher possible upside, research analysts plainly believe Lantheus is more favorable than Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries received 991 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.87% of users gave Teva Pharmaceutical Industries an outperform vote while only 65.89% of users gave Lantheus an outperform vote.
99.1% of Lantheus shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.5% of Lantheus shares are owned by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than Lantheus. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 12 mentions for Lantheus. Lantheus' average media sentiment score of 0.98 beat Teva Pharmaceutical Industries' score of 0.88 indicating that Lantheus is being referred to more favorably in the media.
Lantheus has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
Summary
Lantheus beats Teva Pharmaceutical Industries on 13 of the 18 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lantheus Competitors List
Related Companies and Tools
This page (NASDAQ:LNTH) was last updated on 2/21/2025 by MarketBeat.com Staff